期刊文献+

中医综合方案联合化疗治疗Ⅳ期非小细胞肺癌的多中心随机对照研究 被引量:12

Multi-centered randomized controlled study of Chinese medicine integrated with chemotherapy for stageⅣnon-small cell lung cancer
下载PDF
导出
摘要 目的验证中医综合方案联合化疗治疗Ⅳ期非小细胞肺癌的疗效和安全性。方法通过多中心、前瞻性随机对照设计,纳入Ⅳ期非小细胞肺癌患者263例,随机分为观察组135例,对照组128例。观察组给予标准化疗方案联合中医综合方案,对照组接受单纯标准化疗方案。21~28 d为1个周期,连续治疗2个周期后,评估疗效和安全性。结果治疗2个周期后,观察组患者身体健康领域评分高于对照组(P<0.05),观察组身体健康、情绪健康和肺癌其他情况3个领域评分均显著高于治疗前(P<0.05);观察组中医症状总有效率优于对照组(P<0.05);观察组食欲下降、呕吐总发生率及≥3级食欲下降发生率均低于对照组(P<0.05);实体瘤疗效2组间差异无统计学意义(P>0.05)。结论Ⅳ期非小细胞肺癌患者采用中医综合方案联合化疗较单纯化疗在肿瘤控制率方面疗效相当,但能够显著改善中医症状,降低消化道不良反应的发生,提高患者生活质量。 Objective To verify the efficacy and safety of comprehensive TCM regimen combined with chemotherapy in the treatment of stageⅣnon-small cell lung cancer.Methods A total of 263 patients with stageⅣnon-small cell lung cancer were enrolled in this study in a multi-centered,prospective randomized controlled design.They were randomly divided into a observation group(n=135)and a control group(n=128).The observation group received standard chemotherapy combined with TCM comprehensive regimen,while the control group received standard chemotherapy alone.The efficacy and safety were evaluated after 2 consecutive cycles with 21~28 days as one circle.Results After 2 cycles,the PWB(Physical Well-Being)score in test group was significantly higher than that in control group.The three Liang Yu scores of physical health,emotional health and other conditions of lung cancer in observation group were significantly higher than those before treatment(P<0.05).The total effective rate of TCM symptoms in observation group is better than that in control group(P<0.05).The total incidence of anorexia,vomiting and≥3 grade anorexia in observation group were lower than those in control group(P<0.05).There was no statistical difference in the efficacy of solid tumor between the two groups(P>0.05).Conclusion Patients with stageⅣnon-small cell lung cancer who adopt the comprehensive regimen of traditional Chinese medicine combined with chemotherapy have the same effect as chemotherapy alone in terms of tumor control rate,but can significantly improve the symptoms of TCM,reduce the occurrence of adverse reactions in gastrointestinal tract,and make the patients have a better quality of life.
作者 宋丽君 马雪娇 郑佳彬 王学谦 张英 刘杰 侯炜 林丽珠 蒋益兰 解英 李平 王沈玉 张洪亮 舒琦瑾 林洪生 SONG LI-jun;MA Xue-jiao;ZHENG Jia-bin;WANG Xue-qian;ZHANG Ying;LIU Jie;HOU Wei;LIN Li-zhu;Jiang YI-Lan;XIE Ying;LI Ping;WANG Shen-yu;ZHANG Hong-liang;SHU Qi-jin;LIN Hong-sheng(Department of Oncology,Guang’anmen Hospital,China Academy of Chinese Medical Sciences,Beijing 100053,China;Internal Oncology Department of Integrated Traditional Chinese and Western Medicine,China-Japan Friendship Hospital,Beijing 100029;Department of Oncology,The First Affiliated Hospital of Guangzhou University of Chinese Medicine,Guangzhou 510405;Department of Oncology,The Affiliated Hospital of Hunan Academy of Chinese Medicine,Changsha 410006;Department of Traditional Chinese Medicine,Shanxi Tumor Hospital,Taiyuan 030013;Department of Oncology of Integrated Traditional Chinese and Western Medicine,the First Affiliated Hospital of Anhui Medical University,Hefei 230038;Department of Integrated Traditional Chinese and Western Medicine,Liaoning Cancer Hospital,Shenyang 110042;Department of Oncology,The Xinjiang Uygur Autonomous Region Hospital of Traditional Chinese Medicine,Urumqi 830000;Department of Oncology,Zhejiang Hospital of Traditional Chinese Medicine,Hangzhou 310053)
出处 《北京中医药》 2022年第1期2-6,共5页 Beijing Journal of Traditional Chinese Medicine
基金 国家中医药行业科研专项(201307006) 国家国际科技合作专项(2013DFA325)。
关键词 非小细胞肺癌 Ⅳ期 中医综合治疗 化疗 不良反应 中医症状 生活质量 Non-small cell lung cancer(NSCLC) stageⅣ comprehensive treatment of traditional Chinese medicine chemotherapy adverse reaction TCM symptom quality of life
  • 相关文献

参考文献4

二级参考文献28

  • 1刘基巍,陈俊霞,于丽华,田余祥,崔秀云,燕秋,富力.人参皂甙Rg3和核糖核酸酶抑制因子转基因对小鼠黑色素瘤的抑制作用研究[J].中华肿瘤杂志,2004,26(12):722-725. 被引量:30
  • 2易成,黄晓兵,侯梅.化疗联合人参皂甙Rg3治疗肺癌的实验研究[J].中国中西医结合杂志,2005,25(1):58-59. 被引量:29
  • 3王金万,孙燕,刘永煜,于起涛,张沂平,李凯,朱允中,周清华,侯梅,管忠震,李维廉,庄武,王东林,梁后杰,秦凤展,卢辉山,刘晓晴,孙红,张燕军,王杰军,罗素霞,杨瑞合,涂远荣,王秀问,宋恕平,周静敏,游丽芬,王竞,姚晨.重组人血管内皮抑素联合NP方案治疗晚期NSCLC随机、双盲、对照、多中心Ⅲ期临床研究[J].中国肺癌杂志,2005,8(4):283-290. 被引量:626
  • 4张芷旋,周清华.中药抗肺癌血管生成药物的研究进展[J].中国肺癌杂志,2006,9(1):96-99. 被引量:9
  • 5中华人民共和国卫生部医政司编.常见恶性肿瘤诊治规范.北京:中国协和医科大学出版社,1999:773-781.
  • 6Mountain CF.Revisions in the international system for staging lung cancer.Chest 1997; 111 (6):1710-1717.
  • 7Johnson JR,Temple R.Food and Drug Administration requirements for approval of new anti-cancer drugs.Cancer Treat Rep 1985 ;69(10):1155-1159.
  • 8Anderson H,Hopwood P,Stephens RJ,et al.Gemcitabine plus best supportive care (BSC) vs BSC in inoperable nonsmall cell lung cancer-a randomized trial with quality of life as the primary outcome.Br J Cancer 2000;83 (4):447-453.
  • 9Cardenal F,Lopez-Cabrerizo MP,Anton A,et al.Randomized phase Ⅲ study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer.J Clin Oncol 1999;17(1):12-18.
  • 10Herndon JE,Fleishman S,Kornblith AB,et al.Is quality of life predictive of the survival of patients with advanced nonsmall cell lung cancinoma? Cancer 1999; 85 (2):333-340.

共引文献3804

同被引文献191

引证文献12

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部